MediWound (MDWD)
(Delayed Data from NSDQ)
$17.08 USD
-0.79 (-4.42%)
Updated Oct 15, 2024 03:57 PM ET
After-Market: $17.04 -0.04 (-0.23%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.08 USD
-0.79 (-4.42%)
Updated Oct 15, 2024 03:57 PM ET
After-Market: $17.04 -0.04 (-0.23%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Zacks News
MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of -61.90% and 0.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -1.69% and 11.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AST SpaceMobile (ASTS) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
AST SpaceMobile (ASTS) is expected to report top-line growth year over year in the second quarter of 2024, backed by healthy demand in several sectors.
PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -16% and 2.82%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 48% and 14.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
MediWound (MDWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings
by Zacks Equity Research
Improvement in RPT and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the second quarter.
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
by Zacks Equity Research
Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.
Can MediWound (MDWD) Climb 57.49% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 57.5% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of 2.50% and 6.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -20% and 6.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 52.63% and 0.25%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Century Therapeutics (IPSC) delivered earnings and revenue surprises of 10% and 185%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
by Zacks Equity Research
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for MediWound (MDWD) points to a 76.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What Makes MediWound (MDWD) a Good Fit for 'Trend Investing'
by Zacks Equity Research
MediWound (MDWD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of 17.39% and 0.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
by Zacks Equity Research
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -15.63% and 7.58%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 134.8% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MediWound (MDWD): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
MediWound (MDWD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Wall Street Analysts Believe MediWound (MDWD) Could Rally 171.79%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 171.8% in MediWound (MDWD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 223.1% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.